Exercise in Camurus’ employee stock options program 2021/2024

Lund, Sweden — 19 September 2024 — During September 2024, a total of 142,300 options in Camurus AB’s employee stock options program ESOP 2021/2024 have been exercised for the corresponding number of shares, at an exercise price of SEK 263.50 per share. Through the exercise of the employee stock options, Camurus receives a total of SEK 37.5 million.

A number of employees of Camurus, including the company’s CEO, have participated in two forms of cashless exercise, where shares have been sold either in such number that was required to finance the subscription of new shares and taxes related to the exercise of the employee stock options, or in such number of shares that corresponded to the number of employee stock options exercised by the participant.

The exercise period for ESOP 2021/2024 ends on 16 December 2024.

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

The information was submitted for publication at 3.30 pm CEST on 19 September 2024.